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Objectives The aims of this study were to examine prospectively the relationship between metabolic syndrome (MetS) and
aortic stenosis (AS) progression and to evaluate the effect of age and statin therapy on AS progression in pa-
tients with or without MetS.
Background Despite the clear benefits of statin therapy in primary and secondary coronary heart disease prevention, several
recent randomized trials have failed to demonstrate any significant effect of this class of drugs on the progres-
sion of AS. Previous retrospective studies have reported an association between MetS and faster AS progression.
Methods This predefined substudy included 243 of the 269 patients enrolled in the ASTRONOMER (AS Progression Obser-
vation: Measuring Effects of Rosuvastatin) trial. Follow-up was 3.4  1.3 years. AS progression rate was mea-
sured by calculating the annualized increase in peak aortic jet velocity measured by Doppler echocardiography.
Results Patients with MetS (27%) had faster stenosis progression (0.25  0.21 m/s/year vs. 0.19  0.19 m/s/year,
p  0.03). Predictors of faster AS progression in multivariate analysis were older age (p  0.01), higher degree
of valve calcification (p  0.01), higher peak aortic jet velocity at baseline (p  0.007), and MetS (p  0.005).
Impact of MetS on AS progression was most significant in younger ( 57 years) patients (MetS: 0.24  0.19
m/s/year vs. no MetS: 0.13  0.18 m/s/year, p  0.008) and among patients receiving statin therapy
(0.27  0.23 m/s/year vs. 0.19  0.18 m/s/year, p  0.045). In multivariate analysis, the MetS-age inter-
action was significant (p  0.01), but the MetS-statin use interaction was not.
Conclusions MetS was found to be a powerful and independent predictor of faster AS progression, with more pronounced
impact in younger patients. These findings emphasize the importance of routinely identifying and treating MetS
in AS patients. The apparent faster stenosis progression in the subset of normocholesterolemic patients with
MetS receiving the statin will need to be confirmed by future studies. (J Am Coll Cardiol 2012;60:216–23)
© 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.052Recent studies suggest that calcific aortic stenosis (AS) is
not a passive degenerative disease resulting from decades of
repetitive mechanical stress, but rather an active disease that
involves the interaction of several pathways, including lipid
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be a modifiable disease. Experimental animal studies as well
as several retrospective clinical studies initially reported that
low-density lipoprotein (LDL)-lowering therapy with st-
atins may reduce stenosis progression (2–4). One open-
label prospective study also reported that hypercholester-
olemic patients treated with statins had significantly slower
AS progression compared with normocholesterolemic pa-
tients with a similar degree of AS but who were left
untreated (5). However, 3 subsequent randomized trials
performed in normocholesterolemic patients (SALTIRE
[Scottish Aortic Stenosis and Lipid Lowering Trial], SEAS
[Simvastatin and Ezetimibe in Aortic Stenosis] trial, and
the ASTRONOMER [AS Progression Observation: Mea-
suring Effects of Rosuvastatin] trial) failed to demonstrate
any significant effect of statins on either stenosis progression
or occurrence of valve-related events (6–8).
In a single-center retrospective study of 105 patients with
AS, we previously reported that MetS was associated with
faster AS progression and with a higher rate of adverse
events (i.e., aortic valve replacement [AVR], death, or both)
(9). Other retrospective or cross-sectional studies also re-
vealed independent associations between MetS and in-
creased prevalence of aortic valve calcification (10) or faster
degeneration of bioprosthetic aortic valves (11). These
findings lend support to the hypothesis that MetS could be
associated with faster AS progression independently of the
traditional risk factors, and in particular LDL cholesterol
level. The objectives of this predefined substudy of the
ASTRONOMER trial (ISRCTN32424163) were: 1) to exam-
ine the relationship between theMetS and the progression of AS;
and 2) to assess the effect of age and statin therapy on AS
progression in the patients with or without MetS.
Methods
The design and core results of the ASTRONOMER trial
have been reported previously (8,12). The design and
protocol of the present substudy were established before the
conduct of the main study.
Patient population. The ASTRONOMER trial included
269 patients (age range: 18 to 82 years) with mild to
moderate AS (peak aortic jet velocity [Vpeak]: 2.5 to 4.0 m/s)
recruited in 23 Canadian sites between 2002 and 2005.
Exclusion criteria were severe or symptomatic AS, severe
aortic regurgitation, mitral valve disease (mitral stenosis or
severe mitral regurgitation), symptomatic coronary artery
disease, congestive heart failure, diabetes, or need for
cholesterol-lowering treatment. Patients were randomized
to rosuvastatin 20 mg versus placebo. Twenty-six patients
(10%) were excluded from this substudy because waist
circumference data, Doppler echocardiographic follow-up
data, or both were not available. Hence, we analyzed the
clinical, laboratory, and Doppler echocardiographic data of
the 243 remaining patients (90%).Clinical data. Clinical data in-
cluded age, gender, history of
smoking, documented diagnosis
of hypertension (patients taking
antihypertensive medications or
with known but untreated hyper-
tension: blood pressure 130/85
m Hg) and randomization group
statin or placebo).
etabolic profile. ANTHRO-
POMETRIC MEASURES. Weight,
eight, body mass index, and waist
ircumference were determined fol-
owing the standard procedures (13).
LABORATORY DATA. Fasting
blood samples were collected at
baseline, 1 year, and last follow-up
to obtain plasma levels of glu-
cose, insulin, and creatinine and
complete lipid profile, which included total cholesterol,
triglycerides, LDL cholesterol, high-density lipoprotein
cholesterol, and apolipoprotein B using automated tech-
niques standardized with the Canadian reference laboratory.
After centrifugation, plasma samples were stored at 80°C
until measurement of LDL particle size, as previously
described (14). To assess insulin resistance, we calculated
the homeostatic assessment model (HOMA) index using the
formula: insulin (U/ml)·[glucose (mmol/l)/22.5] (15).
IDENTIFICATION OF PATIENTS WITH METABOLIC SYN-
DROME. The clinical identification of patients with the
features of MetS was based on the modified criteria pro-
posed by the National Cholesterol Education Program–
Adult Treatment Panel III (16).
Doppler echocardiographic data. The echocardiographers
at each site received training in the acquisition and inter-
pretation of the echocardiograms before the beginning of
the study. Randomly selected studies that contributed 10%
of the total number of echocardiograms were reviewed to
ensure that the studies and measurements were performed
in accordance with the protocol.
AORTIC VALVE CONFIGURATION AND FUNCTION. The
Doppler echocardiographic indices of AS severity included
Vpeak, peak and mean transvalvular pressure gradients ob-
tained with the use of the modified Bernoulli equation, and
the aortic valve area (AVA) calculated by the standard
continuity equation. The AVA could not be determined in
19% (n  45) of the patients because of subvalvular flow
acceleration or inadequate measure of left ventricle (LV)
outflow tract diameter. The Doppler velocity index (DVI)
was computed by dividing the flow velocity time integral in
the LV outflow tract by the aortic jet velocity time integral.
The degree of aortic valve calcification was scored (1: none;
2: mild; 3: moderate; 4: severe) according to the criteria
Abbreviations
and Acronyms
AS  aortic stenosis
AVA  aortic valve area
AVR  aortic valve
replacement
DVI  Doppler velocity
index
HOMA  homeostatic
assessment model
LDL  low-density
lipoprotein
LV  left ventricle
MetS  metabolic
syndrome
NS  not significant
Vpeak  peak aortic jet
velocityproposed by Rosenhek et al. (17).
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atio was calculated by dividing the sum of the LV posterior
all and interventricular septal thicknesses by the LV
nternal dimension (18). LV mass was calculated with the
orrected formula of the American Society of Echocardiog-
aphy and was indexed to a 2.7 power of height (19). As a
easure of global LV hemodynamic load, we calculated the
alvuloarterial impedance (20): Zva  (SBP  Pmean)/SVi
where SBP is the systolic blood pressure, Pmean is the mean
ransvalvular gradient, and SVi is the stroke volume indexed
o a 2.04 power of height (19).
tudy outcomes. The primary outcome for this study was
he progression rate of valve stenosis measured by Doppler
chocardiography. To account for different follow-up
engths, annualized changes in peak aortic jet velocity,
VA, and DVI were calculated by dividing the total change
y length of follow-up. The secondary outcome was the
omposite of AVR or cardiac death.
tatistical analysis. Continuous data were expressed as
ean  SD. The continuous variables were tested for
ormality of distribution and homogeneity of variances with
he Shapiro-Wilk and Levene tests, respectively. These
ariables then were compared between patients with and
ithout MetS using the unpaired Student t test. Categorical
ata were expressed as a percentage and were compared with
he chi-square test. Multivariate linear regression analysis
as performed to identify the independent predictors of
aster AS progression (i.e., annualized progression rates of
eak aortic jet velocity, AVA, and DVI). We entered in the
ultivariate model: 1) the variables with p value 0.10 in
ndividual analysis; 2) the traditional cardiovascular risk
actors (age, male gender, history of hypertension, LDL
holesterol, and history of smoking); 3) the aortic valve
henotype (bicuspid vs. tricuspid); and 4) the randomiza-
ion status (statin vs. placebo). A second multivariate model
as obtained by including the interaction terms: MetS·age
nd MetS·statin use. A 1-way analysis of variance followed
y a Tukey post-hoc test was used to evaluate the effect of
etS and age (dichotomized according to the median value:
7 years of age) or statin therapy on stenosis progression.
aplan-Meier curves and log-rank tests of the time-to-event
ata were used to assess the effect of MetS on the composite of
VR or cardiac death. The predictors of event-free survival
ere assessed with the use of individual and multivariate Cox
roportional hazard analyses. Two- or 3-way analyses of
ariance for repeated measures followed by a Tukey post hoc
est were used to determine the effect of treatment (statin vs.
lacebo), group (MetS vs. no MetS), and time (baseline vs.
-year follow-up) on blood metabolic markers. A p value of
0.05 was considered statistically significant.
esults
aseline characteristics of the study population. Among
he 243 patients included in this study (mean follow-up:
.4  1.3 years), 30% had systemic arterial hypertension, 746% had a history of smoking, and 27% hadMetS according
to the National Cholesterol Education Program–Adult
Treatment Panel III criteria (Table 1). Baseline Doppler
echocardiographic data showed significantly higher relative
wall thickness ratio and LV mass index and a nonsignificant
trend for lower prevalence of bicuspid aortic valve in the
patients with MetS, whereas the degree of aortic valve calcifi-
cation, Vpeak, transvalvular pressure gradients, AVA, DVI,
and LV ejection fraction were similar in both groups
(Table 1).
Impact of MetS on AS progression and interaction with age.
AS progression rate was significantly higher in patients with
MetS compared with those without MetS: annualized
progression rate of Vpeak: 0.25  0.21 m/s/year vs. 
.19  0.19 m/s/year, p  0.03 (Fig. 1A); annualized
rogression rate of AVA: 0.10  0.06 cm2/year vs. 0.07 
0.07 cm2/year, p  0.005; annualized progression rate of
VI: 0.025  0.018 vs. 0.016  0.019, p  0.004.
Baseline variables independently predicting Vpeak progres-
sion rate in multivariate analysis were older age (p  0.01),
higher degree of aortic valve calcification (p  0.01), higher
Vpeak at baseline (p  0.007), and MetS (p  0.005)
Online Table 1). MetS also was found to be an indepen-
ent predictor of AVA (p  0.03) or DVI (p  0.02)
rogression rates.
The impact of the MetS on AS progression differed
epending on patient’s age (MetS·age interaction: p 0.01)
Online Table 1). In patients 57 years of age or younger
median age for the entire cohort), the AS progression rate
as 2-fold faster in subjects with MetS versus those without
etS (Vpeak annualized change: 0.24  0.19 m/s/year vs.
0.13  0.18 m/s/year, p  0.008; AVA annualized
change:0.10 0.06 cm2/year vs.0.05 0.07 cm2/year,
 0.004; DVI annualized change: 0.024  0.017 vs.
0.010  0.017, p  0.002), whereas AS progression was
nchanged in the older patients (age57 years) with or without
etS (Vpeak annualized change: 0.26  0.24 m/s/year vs.
0.25  0.19 m/s/year, p  not significant [p  NS];
VA annualized change: 0.10  0.06 cm2/year vs. 0.08 
.08 cm2/year, p  NS; DVI annualized change: 0.027 
0.019 vs.0.021 0.020, p NS) (Fig. 1B). In the subset
f patients 57 years of age or younger, multivariate analysis
howed that the only significant predictors of faster Vpeak
progression were MetS (p 0.0009) and moderate or severe
aortic valve calcification score of 3 or more (p 0.01). MetS
also was an independent predictor of faster AVA (p 
.009) or DVI (p  0.006) decrease in these younger
atients.
mpact of MetS on clinical outcomes. During follow-up,
here were 53 AS-related events, of which 51 were AVRs
nd 2 were cardiac deaths. The 4-year event-free survival in
atients with MetS versus no MetS was 63  10% versus
80  5% (p  0.18) in the entire cohort (Online Fig. 1A),
51  15% versus 90  5% (p  0.0006) in the subset of
atients 57 years of age or younger (Online Fig. 1B), and
5  15% vs. 68  8% (p  0.30) in the subset of patients
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July 17, 2012:216–23 Impact of Metabolic Syndrome on Aortic Stenosisolder than 57 years (Online Fig. 1C). In patients 57 years of
age or younger, MetS was a predictor of events in individual
analysis (hazard ratio: 4.04, 95% confidence interval: 1.69 to
9.75, p  0.002) and remained a powerful predictor after
adjusting for age, peak aortic jet velocity, and degree of valve
calcification (hazard ratio: 3.86, 95% confidence interval:
1.57 to 9.61, p  0.004).
Effect of statin therapy. As previously reported for the
main ASTRONOMER trial (8), statin therapy had no effect
n AS progression in the entire cohort (Online Table 1). A
ubanalysis with respect to the presence or absence of MetS
Baseline Characteristics of the Study PopulatioTable 1 Baseline Characteristics of the Stu
Variables
All P
(N 
Clinical data
Age (yrs) 57
Male (%) 6
Height (cm) 170
Weight (kg) 81
Body surface area (m2) 1.91
Body mass index (kg/m2) 28
Waist circumference (cm) 95
History of hypertension (%) 3
Systolic blood pressure (mm Hg) 126
Diastolic blood pressure (mm Hg) 75
History of smoking (%) 4
Medication
Antihypertensive treatment (%) 1
ACE inhibitors (%)
ARBs (%)
Rosuvastatin (%) 5
Laboratory data
LDL cholesterol (mmol/l) 3.25
LDL peak particle size (Å) 257.1
Apo B (g/l) 1.02
HDL cholesterol (mmol/l) 1.47
Triglycerides (mmol/l) 1.37
Fasting glucose (mmol/l) 5.2
Fasting insulin (U/ml) 7.
HOMA index 1.9
Creatinine (mol/l) 80
Doppler echocardiographic data
Bicuspid aortic valve (%) 5
Aortic valve calcification score 1.7
Peak aortic jet velocity (m/s) 3.17
Peak transvalvular gradient (mm Hg) 41
Mean transvalvular gradient (mm Hg) 23
Aortic valve area (cm2) 1.35
Indexed aortic valve area (cm2/m2.04) 0.46
Doppler velocity index 0.34
Valvuloarterial impedance (mm Hg/ml/m2.04) 4.8
Relative wall thickness ratio 0.44
LV mass index (g/m2.7) 48
LV ejection fraction (%) 66
Values are mean  SD or %.
ACE  angiotensin-converting enzyme; ARBs  angiotensin recepto
HOMA  homeostatic assessment model; LDL  low-density lipoprotnd treatment assignment, however, revealed that rosuvas-atin treatment was associated with faster AS progression in
atients with MetS than in those with no MetS (Vpeak
annualized change: 0.27  0.23 m/s/year vs. 0.19 
.18 m/s/year, p  0.045) (Fig. 1C) (AVA annualized
hange:0.10 0.06 vs. cm2/year0.06 0.06 cm2/year,
 0.02, DVI annualized change: 0.024  0.018 vs.
0.014  0.016, p  0.02). In patients who received
lacebo, the AS progression rate was not different between
atients with or without MetS (Vpeak: 0.23  0.19
/s/year vs. 0.19  0.21 m/s/year, pNS, AVA:0.09
.06 cm2/year vs. 0.07  0.09 cm2/year, p  NS, DVI
pulation
s
)
No MetS
(n  177; 74%)
MetS
(n  66; 27%) p Value
56 14 5912 NS
61% 65% NS
170 9 170 11 NS
77 14 92 18 0.0001
1 1.88 0.20 2.02 0.22 0.0001
27 4 32 6 0.0001
91 13 103 12 0.0001
22% 52% 0.0001
123 15 137 15 0.0001
73 9 81 11 0.0001
43% 56% 0.09
13.1% 22.2% 0.09
8.5% 12.7% NS
4.5% 9.5% NS
51% 50% NS
2 3.26 0.73 3.25 0.72 NS
257.3 3.8 256.3 3.5 0.07
9 1.01 0.19 1.05 0.19 NS
2 1.56 0.42 1.24 0.31 0.0001
8 1.16 0.52 1.93 0.75 0.0001
5.1 0.5 5.6 0.8 0.0001
6.1 3.9 12.3 7.1 0.0001
1.4 1 3.1 1.9 0.0001
80 16 81 16 NS
55% 43% 0.09
1.7 0.7 1.7 0.7 NS
1 3.17 0.41 3.18 0.40 NS
41 11 41 10 NS
23 7 23 7 NS
2 1.35 0.42 1.36 0.44 NS
4 0.46 0.14 0.47 0.16 NS
8 0.34 0.08 0.33 0.08 NS
4.7 1.4 5.1 1.5 0.07
9 0.43 0.09 0.48 0.09 0.0003
46 14 53 14 0.001
66 6 66 6 NS
ers; Apo B  apolipoprotein B; HDL  high-density lipoprotein;
 left ventricle; MetS  metabolic syndrome; NS  not significant.ndy Po
atient
243
 13
2%
 10
 17
 0.2
 5.6
 14
0%
 17
 10
6%
5.2%
9.5%
5.8%
1%
 0.7
 3.7
 0.1
 0.4
 0.6
 0.6
8 5.7
 1.5
 16
1%
 0.7
 0.4
 11
 7
 0.4
 0.1
 0.0
 1.4
 0.0
 14
 6annualized change: 0.026  0.018 vs. 0.017  0.023,
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MetS·statin use interaction term was not statistically
significant.
As expected, LDL cholesterol level decreased markedly
from baseline to the 1-year follow-up in the patients treated
with statin, whereas there was a minimal reduction in the
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Figure 1
Annualized Progression of Peak
Aortic Jet Velocity According to
Presence or Absence of Metabolic Syndrome
Comparison of metabolic syndrome (MetS) versus no MetS groups (A) in the
entire cohort, (B) after dichotomization by median value of age, and (C) after
dichotomization according to randomization status (statin vs. placebo).
*p  0.001, §p  0.001,†p  0.008, versus no MetS age 57 years group;
‡p  0.045 versus no MetS statin group. Error bars represent the SEM.
Vpeak  peak aortic jet velocity.patients who received placebo (absolute change: 1.86 0.77 mmol/l vs. 0.24  0.68 mmol/l, p  0.001) (Online
Table 2). However, the LDL peak particle size decreased
significantly in the statin group (absolute change: 1.1 
5.0 Å vs. 0.7  4.7 Å, p  0.01) and became significantly
different from that of the placebo group at the 1-year
follow-up (Online Table 2). The HOMA index increased
significantly in the patients treated with statin, whereas it
remained stable in those who received placebo (0.41 
1.15 vs. 0.01  0.88, p  0.004), and this was observed
in the entire cohort as well as in the patients with or without
MetS (Online Table 2), but the 1-year change in HOMA
index associated with statin therapy was greater (p  0.03)
in the patients with MetS (0.78  1.74) compared with
those with no MetS (0.28  0.81) (Online Table 2).
Moreover, the annualized change (from baseline to last
follow-up) in the HOMA index was more important (p 
0.02) in patients with MetS (0.45  1.25 U/year) com-
pared with those without MetS (0.16 0.41 U/year), and
the patients with MetS who were receiving rosuvastatin
treatment by far had the largest increase in HOMA index
(0.61  1.41 U/year) during follow-up (Fig. 2).
When adding the annualized changes in blood metabolic
markers into the multivariate model, the independent de-
terminants of AS progression in the entire cohort were older
age (p  0.038), higher degree of aortic valve calcification
(p  0.039), higher Vpeak (p  0.048), MetS (p  0.017),
and annualized change in HOMA index (p  0.027). The
baseline values of LDL or high-density lipoprotein choles-
terol levels and their annualized changes were not associated
significantly with AS progression.
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(n=71)
§
Figure 2
Annualized Change of
Homeostatic Assessment Model Index
as a Function of MetS and Statin Therapy
Annualized change in homeostatic assessment model (HOMA) index in patients
with MetS versus those with no MetS after dichotomization according to ran-
domization status. §p  0.02 versus no MetS statin group and no MetS pla-
cebo group. Error bars represent SEM. Abbreviation as in Figure 1.
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The main findings of the present study are as follows: 1) this
is the first prospective study to demonstrate that MetS is
associated with faster stenosis progression and poorer prog-
nosis in patients with AS; 2) this detrimental impact of
MetS on AS progression and prognosis is significant only in
younger patients, that is, those 57 years of age and younger,
and not in older ones; 3) statin therapy was associated with
a deterioration of patients’ insulin resistance and the induc-
tion of the small LDL phenotype in this cohort of patients
with normal LDL cholesterol levels, and theses effects were
more pronounced in those patients with a clinical diagnosis
of the MetS; 4) in this latter subset of patients, we also
observed that statin therapy was associated with faster
progression of AS, but multivariate analysis revealed no
significant independent effect of statin and no significant
interaction between MetS and statin use.
Interaction between MetS and age. The findings of this
study suggest that the pathophysiological mechanisms lead-
ing to the development and progression of AS may be, at
least in part, different between the older population and the
younger middle-aged population. These findings are con-
sistent with our previous study of explanted AS valves in
which the small, dense LDL phenotype was associated with
aortic valve inflammatory and calcifying processes in
middle-aged but not in elderly patients (21). Hence, the
insulin-resistant state and atherogenic dyslipidemia linked
to visceral obesity may have a predominant role in the
development of aortic valve inflammation and calcification
in the younger population, whereas other mechanisms may
be involved to a greater degree in the older population,
including dysregulation in the mineral metabolism, post-
menopausal deficiency in estrogen, and age-related modifi-
cation in the adipokine system (21–23).
Statin therapy in normocholesterolemic patients with
both AS and MetS. In this study, statin therapy with
rosuvastatin was found to be associated with worsening
metabolic abnormalities (insulin resistance and small LDL
peak particle size), which often are present in patients with
MetS. In particular, the HOMA index, which reflects
insulin resistance, deteriorated significantly only in patients
receiving statin therapy and to a much greater extent in
patients with MetS (Fig. 2, Online Table 2). These results
are consistent with several recent reports. A randomized
study by Koh et al. (24) showed that atorvastatin causes
insulin resistance and increases ambient glycemia in hyper-
cholesterolemic patients. Moreover, several large-scale clin-
ical trials have demonstrated that lipophilic statins such as
atorvastatin, simvastatin, and rosuvastatin may be associated
with an increased risk of new-onset type II diabetes (25–27).
In a recent meta-analysis of 3 large randomized trials,
treatment with high-dose atorvastatin increased the risk of
new-onset diabetes to a larger extent in the patients with
MetS compared with those with no MetS (28). In this
context, it thus is not surprising that the deleterious effectsof MetS on AS progression and metabolic profile were more
pronounced in the patients treated with rosuvastatin, be-
cause both MetS and statin treatment seemed to be acting
in synergy to increase insulin resistance and to decrease
LDL peak particle size. A tendency toward a synergy
between MetS and statin therapy with faster AS progression
or accelerated aortic valve bioprosthesis degeneration also
has been observed in 2 retrospective studies from our group
(9,11).
Clinical perspectives. We propose that this study has
important clinical implications. The role of MetS as an
independent predictor of faster AS progression is con-
firmed, and importantly, this detrimental effect is observed
even if total or LDL cholesterol levels are normal. Hence,
newer therapeutic targets in AS logically should be aimed at
treating the risk factors associated with MetS when present
and should include aggressive lifestyle changes such as
increased physical activity and dietary changes aimed at
weight loss, particularly at the loss of visceral or ectopic fat,
which is so closely related to the presence of the MetS (29).
Unfortunately long-term patient compliance with lifestyle
changes is difficult to achieve, and specific pharmacological
therapies directed toward visceral obesity are not yet avail-
able. Nonetheless, the findings of the present study provide
additional evidence for motivating patients to achieve better
long-term compliance regarding these lifestyle changes.
The SALTIRE, SEAS, and ASTRONOMER trials
have provided compelling evidence that statins are not
helpful in the treatment of AS (6–8). Nonetheless, in light
of earlier studies that largely were retrospective and reported
positive results, the perception of a possible benefit has
lingered to the extent that many patients with AS, and yet
with no indication for statins, probably are still receiving
statin treatment based on the adage that it cannot harm and
may help. The wisdom of such an approach, however, is
challenged by the present observation of a marked worsen-
ing of insulin resistance and a faster stenosis progression in
the subset of patients with MetS and normal cholesterol
levels. Because of the small number of patients in this
analysis and the lack of significant interaction between
MetS and statin therapy in the entire cohort, these results
should be considered hypothesis generating and must be
evaluated in future trials. Furthermore in the SEAS trial, it
has been reported that the combination of simvastatin and
ezetimibe reduced the risk of ischemic events, especially the
need for coronary artery bypass graft (7). Hence, consider-
ing the very significant benefits associated with statin use in
patients at increased risk of coronary heart disease, including
those with the MetS (27,30), the dilemma of the tradeoff
between reducing coronary heart disease risk and potentially
accelerating AS progression with statin use in normocho-
lesterolemic patients with MetS will have to be addressed
and debated.
Study limitations. The AVA data were not available in
19% of the patients included in this cohort. However, the
results of the annualized changes in AVA were highly
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more, the ASTRONOMER trial was not powered to assess
valve-related events, which limited our ability to perform
multivariable analyses for this outcome.
In view of the relatively small number (n  33) of
patients with MetS who were being treated with statins, the
subanalysis with respect to the effect of statin therapy on AS
progression in patients with MetS is at risk of a type I error.
Furthermore, the MetS·statin use interaction was not sta-
tistically significant in the multivariate analysis of the entire
cohort. A larger study thus is needed to confirm the effect of
statin therapy on AS progression in the subset of patients
with MetS and normal LDL cholesterol levels. Nonethe-
less, the marked deterioration of the metabolic profile
associated with statin therapy in normocholesterolemic
patients with MetS provides some support to the hypoth-
esis of an unwanted side effect of statin therapy on AS
progression in this subset of patients. Given that the need
for statin therapy was a prespecified exclusion criteria in
the ASTRONOMER trial, the results and conclusions of
this substudy can be applied only to patients with no
hypercholesterolemia.
Conclusions
In the ASTRONOMER trial, MetS was found to be a
powerful and independent predictor of faster AS progres-
sion with more pronounced impact in younger patients.
Treatment with rosuvastatin worsened insulin resistance
state and LDL particle phenotype, particularly in patients
with MetS. These findings emphasize the importance of
systematically identifying and treating MetS in AS patients.
The apparent faster stenosis progression in the subset of
normocholesterolemic patients with MetS receiving the
statin will need to be confirmed by future studies.
Acknowledgments
The authors thank all the investigators of the ASTRON-
OMER trial (Online Appendix). They also thank Isabelle
Gaboury, Lynda Hoey, Judy Keys, and Isabelle Laforest for
their help in data collection and management.
Reprints requests and correspondence: Dr. Philippe Pibarot,
Institut Universitaire de Cardiologie et de Pneumologie de Qué-
bec, 2725 Chemin Sainte-Foy, Québec City, Québec G1V 4G5,
Canada. E-mail: philippe.pibarot@med.ulaval.ca.
REFERENCES
1. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease:
pathogenesis, disease progression, and treatment strategies. Circula-
tion 2005;111:3316–26.
2. Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano
M. Association of cholesterol levels, hydroxymethylglutaryl
coenzyme-a reductase inhibitor treatment, and progression of aortic
stenosis in the community. J Am Coll Cardiol 2002;40:1723–30.
3. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL,
Griffin BP. Effect of hydroxymethylglutaryl coenzyme a reductaseinhibitors on the progression of calcific aortic stenosis. Circulation
2001;104:2205–9.
4. Rosenhek R, Rader F, Loho N, et al. Statins but not angiotensin-
converting enzyme inhibitors delay progression of aortic stenosis.
Circulation 2004;110:1291–5.
5. Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting
aortic valve endothelium to slow the progression of aortic stenosis.
J Am Coll Cardiol 2007;49:554–61.
6. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of
intensive lipid-lowering therapy in calcific aortic stenosis. N Engl
J Med 2005;352:2389–97.
7. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering
with simvastatin and ezetimibe in aortic stenosis. N Engl J Med
2008;359:1343–56.
8. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of lipid lowering
with rosuvastatin on progression of aortic stenosis. Results of the
Aortic Stenosis Progression Observation: Measuring Effects of Rosu-
vastatin (ASTRONOMER) trial. Circulation 2010;121:306–14.
9. Briand M, Lemieux I, Dumesnil JG, et al. Metabolic syndrome
negatively influences disease progression and prognosis in aortic
stenosis. J Am Coll Cardiol 2006;47:2229–36.
0. Katz R, Wong ND, Kronmal R, et al. Features of the metabolic
syndrome and diabetes mellitus as predictors of aortic valve calcifica-
tion in the Multi-Ethnic Study of Atherosclerosis. Circulation 2006;
113:2113–9.
1. Briand M, Pibarot P, Despres JP, et al. Metabolic syndrome is
associated with faster degeneration of bioprosthetic valves. Circulation
2006;114:1512–7.
2. Chan KL, Teo K, Tam J, Dumesnil JG. Rationale, design, and
baseline characteristics of a randomized trial to assess the effect of
cholesterol lowering on the progression of aortic stenosis: the Aortic
Stenosis Progression Observation: Measuring Effects of Rosuvastatin
(ASTRONOMER) trial. Am Heart J 2007;153:925–31.
3. Lohman TG, Roche AF, Martorell R. The Airlie (VA) Consensus
Conference. In: Lohman TG, Roche AF, Martorell R (editors).
Anthropometric Standardization Reference Manual. Champaign, IL:
Human Kinetics 1988;39–80.
4. St Pierre AC, Cantin B, Dagenais GR, et al. Low-density lipoprotein
subfractions and the long-term risk of ischemic heart disease in men:
13-year follow-up data from the Quebec Cardiovascular Study. Arte-
rioscler Thromb Vasc Biol 2005;25:553–9.
5. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF,
Turner RC. Homeostasis model assessment: insulin resistance and
beta-cell function from fasting plasma glucose and insulin concentra-
tions in man. Diabetologia 1985;28:412–9.
6. National Cholesterol Education Program Expert Panel. Executive
summary of the third report of the National Cholesterol Education
Program (NCEP) Expert Panel on detection, evaluation, and treat-
ment of high blood cholesterol in adults (Adults Treatment Panel III).
JAMA 2001;285:2486–92.
7. Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in
severe, asymptomatic aortic stenosis. N Engl J Med 2000;343:611–7.
8. Lang RM, Bierig M, Devereux RB, et al. Recommendations for
chamber quantification: a report from the American Society of
Echocardiography’s Guidelines and Standards Committee and the
Chamber Quantification Writing Group, developed in conjunction
with the European Association of Echocardiography, a branch of the
European Society of Cardiology. J Am Soc Echocardiogr 2005;18:
1440–63.
9. Pagé A, Dumesnil JG, Clavel MA, et al. Metabolic syndrome is
associated with more pronounced impairment of LV geometry and
function in patients with calcific aortic stenosis: a substudy of the
ASTRONOMER trial (Aortic Stenosis Progression Observation: Mea-
suring Effects of Rosuvastatin). J Am Coll Cardiol 2010;55:1867–74.
0. Hachicha Z, Dumesnil JG, Pibarot P. Usefulness of the valvuloarterial
impedance to predict adverse outcome in asymptomatic aortic stenosis.
J Am Coll Cardiol 2009;54:1003–11.
1. Mohty D, Pibarot P, Despres JP, et al. Age-related differences in the
pathogenesis of calcific aortic stenosis: the potential role of resistin. Int
J Cardiol 2010;142:126–32.
2. Akat K, Kaden JJ, Schmitz F, et al. Calcium metabolism in adults with
severe aortic valve stenosis and preserved renal function. Am J Cardiol
2010;105:862–4.
s223JACC Vol. 60, No. 3, 2012 Capoulade et al.
July 17, 2012:216–23 Impact of Metabolic Syndrome on Aortic Stenosis23. Osako MK, Nakagami H, Koibuchi N, et al. Estrogen inhibits vascular
calcification via vascular RANKL system: common mechanism of osteo-
porosis and vascular calcification. Circ Res 2010;107:466–75.
24. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin
causes insulin resistance and increases ambient glycemia in hypercho-
lesterolemic patients. J Am Coll Cardiol 2010;55:1209–16.
25. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and
stroke events with atorvastatin in hypertensive patients who have
average or lower-than-average cholesterol concentrations, in the
Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm
(ASCOT-LLA): a multicentre randomised controlled trial. Lancet
2003;361:1149–58.
26. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart
Protection Study of cholesterol-lowering with simvastatin in 5963
people with diabetes: a randomised placebo-controlled trial. Lancet
2003;361:2005–16.
27. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent
vascular events in men and women with elevated C-reactive protein.
N Engl J Med 2008;359:2195–207.28. Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset
diabetes in patients treated with atorvastatin. J Am Coll Cardiol
20110;14:1535–45.
29. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome.
Nature 2006;444:881–7.
30. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of
cholesterol-lowering treatment: prospective meta-analysis of data from
90,056 participants in 14 randomised trials of statins. Lancet 2005;
366:1267–78.
Key Words: aortic stenosis y Doppler echocardiography y metabolic
yndrome y obesity y statins.
APPENDIX
For supplementary tables and figure,
please see the online version of this article.
